These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 22337287

  • 1. Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.
    Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM.
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):543-50. PubMed ID: 22337287
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M.
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [Abstract] [Full Text] [Related]

  • 3. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J.
    N Engl J Med; 2000 Dec 07; 343(23):1673-80. PubMed ID: 11106716
    [Abstract] [Full Text] [Related]

  • 4. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
    Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK, EPIC3 Study Group.
    Gastroenterology; 2011 Jun 07; 140(7):1990-9. PubMed ID: 21419770
    [Abstract] [Full Text] [Related]

  • 5. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM.
    Hepatology; 2012 Aug 07; 56(2):464-73. PubMed ID: 22334369
    [Abstract] [Full Text] [Related]

  • 6. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V, PERICO Study Group.
    J Infect Dis; 2012 Sep 15; 206(6):961-8. PubMed ID: 22807523
    [Abstract] [Full Text] [Related]

  • 7. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D.
    Gastroenterology; 2014 Feb 15; 146(2):442-52.e1. PubMed ID: 24126097
    [Abstract] [Full Text] [Related]

  • 8. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial.
    Chapplain JM, Bellissant E, Guyader D, Molina JM, Poizot-Martin I, Perré P, Pialoux G, Turlin B, Mouchel C, Renault A, Michelet C, ANRS HC-12 Study Group.
    J Infect; 2013 Oct 15; 67(4):313-21. PubMed ID: 23800784
    [Abstract] [Full Text] [Related]

  • 9. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P.
    Clin Ther; 2010 Aug 15; 32(9):1565-77. PubMed ID: 20974315
    [Abstract] [Full Text] [Related]

  • 10. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
    Roffi L, Colloredo G, Pioltelli P, Bellati G, Pozzpi M, Parravicini P, Bellia V, Del Poggio P, Fornaciari G, Ceriani R, Ramella G, Corradi C, Rossini A, Bruno S, Gruppo Epatologico Lombardo.
    Antivir Ther; 2008 Aug 15; 13(5):663-73. PubMed ID: 18771050
    [Abstract] [Full Text] [Related]

  • 11. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
    Cheong HR, Woo HY, Heo J, Yoon KT, Kim DU, Kim GH, Kang DH, Song GA, Cho M.
    Korean J Hepatol; 2010 Mar 15; 16(1):38-48. PubMed ID: 20375641
    [Abstract] [Full Text] [Related]

  • 12. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators.
    Eur J Gastroenterol Hepatol; 2008 Jul 15; 20(7):680-7. PubMed ID: 18679072
    [Abstract] [Full Text] [Related]

  • 13. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M.
    Lancet; 2014 Aug 02; 384(9941):414-26. PubMed ID: 24907224
    [Abstract] [Full Text] [Related]

  • 14. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.
    Maan R, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Zangneh HF, Lammert F, Manns MP, Zeuzem S, Janssen HL, de Knegt RJ, Veldt BJ.
    J Hepatol; 2014 Sep 02; 61(3):482-91. PubMed ID: 24780302
    [Abstract] [Full Text] [Related]

  • 15. Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.
    Butt AS, Mumtaz K, Aqeel I, Shah HA, Hamid S, Jafri W.
    Trop Gastroenterol; 2009 Sep 02; 30(4):207-12. PubMed ID: 20426280
    [Abstract] [Full Text] [Related]

  • 16. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E, Aghemo A, Colombo M.
    Clin Ther; 2010 Dec 02; 32(13):2117-38. PubMed ID: 21316532
    [Abstract] [Full Text] [Related]

  • 17. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
    He LL, Chen Z, Chen Y, Xu H, Tang H, Lei BJ, Lei XZ.
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan 02; 19(1):34-7. PubMed ID: 21272456
    [Abstract] [Full Text] [Related]

  • 18. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A, Yedibela S, Schuhmann S, Croner R, Schellerer V, Demir R, Hohenberger W, Müller V.
    Transplant Proc; 2011 Dec 02; 43(10):3824-8. PubMed ID: 22172854
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH.
    Am J Kidney Dis; 2013 Oct 02; 62(4):789-95. PubMed ID: 23746377
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
    Urbanek P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Husa P.
    Eur J Gastroenterol Hepatol; 2011 Nov 02; 23(11):1004-10. PubMed ID: 21904204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.